Cellecta, Inc. was founded in April of 2006 by one of the chief scientists from Clontech Laboratories. The contract research company was borne out of the need for higher-quality, more advanced pooled lentiviral shRNA and peptide libraries. Our mission is to develop advanced high-throughput (HT) genetic screen technologies and their applications for the discovery and functional characterization of novel therapeutic targets and drugs.